超越糖尿病:对类似葡萄糖-1受体激动剂的新兴指示的审查

相关实验视频

Updated: Feb 10, 2026

11:45

Quantifying Agonist Activity at G Protein-coupled Receptors

Published on: December 26, 2011

19.8K

Lucianne West¹, Harsh Patolia², Brittany Chapman²

¹Department of Transplant Surgery, Tufts Medical Center, Boston, MA 02111, USA.

Reviews in cardiovascular medicine

|February 9, 2026

概括

类似葡萄糖-1受体激动剂 (GLP-1RA) 对2型糖尿病有效,并越来越多地用于肥胖,心力衰竭,脏疾病和肝脏疾病. 创新旨在改善慢性疾病的获取和持续使用.

科学领域:

药理学和内分泌学药理学和内分泌学
心脏病学心脏病学
腎臟病學 (nephrology) 是一種醫學專業.
肝病学肝病学是一种肝病学.

背景情况:

葡萄糖类-1受体激动剂 (GLP-1RA) 最初是为了2型糖尿病的治疗而开发的.
GLP-1RA表现出超出血糖控制的广泛治疗潜力,影响多个器官系统.
新出现的证据强调了它们在各种心脏代谢疾病中的作用.

研究的目的:

审查GLP-1RA在心脏代谢疾病中的扩展应用.
总结临床试验数据,支持GLP-1 RA在肥胖,心力衰竭,CKD和MASLD中的疗效.
讨论与GLP-1 RA实施相关的挑战和创新.

主要方法:

关于GLP-1RA的临床试验和研究的综合文献综述.
关于减肥,心血管结果和功能维护的数据分析.
对GLP-1 RA治疗当前挑战和未来方向的评估.

主要成果:

GLP-1RA在促进减肥和改善心血管和的结果方面表现出强大的有效性.
临床试验支持在心力衰竭中使用它们,其中包括保留喷射分数,CKD和MASLD.
目前正在进行的试验正在扩大这些迹象的证据基础.

结论:

GLP-1RA是转化剂,在管理复杂的慢性疾病方面发挥着越来越重要的作用.
需要解决成本,访问和遵守方面的挑战,以实现更广泛的实施.
像口服配方和组合疗法这样的创新可能会提高可访问性和持续使用.

关键词:

作为GLP-1受体的激动剂.心血管疾病的结果.类似于葡萄糖的-1 与代谢相关的脂肪性肝病.肥胖管理肥胖管理保护脏保护脏减肥药物治疗药物治疗减肥药物治疗

相关概念视频

01:24

Glucagon-like Receptor Agonists

995

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...

995

01:25

Drug-Receptor Interaction: Agonist

4.1K

Agonists are drugs that interact with specific receptors in the body to produce a biological response. When an agonist binds to a receptor, it activates or enhances the receptor's function, leading to physiological effects. The interaction between agonist drugs and receptors is crucial for their therapeutic action in various medical treatments.
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous...

4.1K

02:39

Indicators

61.1K

Certain organic substances change color in dilute solution when the hydronium ion concentration reaches a particular value. For example, phenolphthalein is a colorless substance in any aqueous solution with a hydronium ion concentration greater than 5.0 × 10−9 M (pH < 8.3). In more basic solutions where the hydronium ion concentration is less than 5.0 × 10−9 M (pH > 8.3), it is red or pink. Substances such as phenolphthalein, which can be used to determine the pH of a solution, are...

61.1K

01:23

Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists

1.0K

Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...

1.0K

01:15

Hypoglycemia and Glucagon

1000

Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...